{"id":"reference-brinzolamide-1-ophthalmic-suspension","safety":{"commonSideEffects":[{"rate":"null","effect":"Blepharitis"},{"rate":"null","effect":"Eye irritation"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL220491","moleculeType":"Small molecule","molecularWeight":"383.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by inhibiting the carbonic anhydrase enzyme in the ciliary epithelium of the eye, which leads to a decrease in the production of aqueous humor. This reduction in intraocular pressure helps to alleviate symptoms of glaucoma and ocular hypertension.","oneSentence":"Reference-Brinzolamide 1% Ophthalmic suspension works by reducing intraocular pressure by increasing the outflow of aqueous humor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:41.938Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of ocular hypertension or glaucoma"}]},"trialDetails":[{"nctId":"NCT04944290","phase":"PHASE3","title":"To Compare the Efficacy and Safety of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2021-05-28","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":447},{"nctId":"NCT05022004","phase":"PHASE3","title":"A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2021-12-20","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":599},{"nctId":"NCT03896633","phase":"PHASE1, PHASE2","title":"Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2018-02-28","conditions":"Glaucoma, Open Angle or Ocular Hypertension","enrollment":637},{"nctId":"NCT04024072","phase":"PHASE3","title":"To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2019-06-24","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":495},{"nctId":"NCT02512042","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-04","conditions":"Glaucoma","enrollment":973}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":184,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Reference-Brinzolamide 1% Ophthalmic suspension","genericName":"Reference-Brinzolamide 1% Ophthalmic suspension","companyName":"Actavis Inc.","companyId":"actavis-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reference-Brinzolamide 1% Ophthalmic suspension works by reducing intraocular pressure by increasing the outflow of aqueous humor. Used for Treatment of ocular hypertension or glaucoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}